Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IDXX
HoldFallen FavouriteIDEXX Laboratories, Inc. · Healthcare · United States · $43.7B · Avg Vol: $299M/d
COMPANY DESCRIPTION
IDEXX Laboratories, Inc. is a global leader in veterinary diagnostics and water quality testing, developing and manufacturing proprietary products and services for companion animals, livestock, and poultry. The company benefits from a substantial installed base of diagnostic instruments in veterinary practices, generating high-margin recurring revenue from consumables and reference laboratory services. Its strong market position is reinforced by high switching costs and continuous innovation in pet healthcare technology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.4B | 3.7B | 3.9B | 4.3B | 8.5% | 4.6B | 4.7B | 5.1B | 9.3% |
| EPS | 8.12 | 10.17 | 10.77 | 13.17 | 17.5% | 14.24 | 14.94 | 16.86 | 13.1% |
| Shares | 82.9M | 83.0M | 81.6M | 79.7M | -3.8% | 78.8M | — | — | — |
| Debt | 1.5B | 1.1B | 986.9M | 976.1M | -12.8% | 1.1B | — | — | — |
| Equity | 608.7M | 1.5B | 1.6B | 1.6B | 38.2% | — | — | — | — |
| Op CF | 543.0M | 906.5M | 929.0M | 1.2B | 29.6% | 1.4B | — | — | — |
| Inv CF | -195.3M | -125.3M | -207.1M | -136.2M | — | — | — | — | — |
| Fin CF | -370.9M | -442.0M | -878.1M | -1.2B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IDXX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IDXX | IDEXX Laboratories, Inc.(you) | $43.7B | 58 | Hold |
| NTRA | Natera, Inc. | $47.0B | 56 | Hold |
| WAT | Waters Corporation | $40.7B | 62 | Hold |
| IQV | IQVIA Holdings Inc. | $43.1B | 73 | Buy |
| A | Agilent Technologies, Inc. | $43.4B | 75 | Buy |
| ILMN | Illumina, Inc. | $32.6B | 75 | Buy |
| DHR | Danaher Corporation | $151.9B | 59 | Hold |
| CRL | Charles River Laboratories International, Inc. | $14.0B | 63 | Hold |
| RVTY | Revvity, Inc. | $14.4B | 64 | Hold |
| GH | Guardant Health, Inc. | $21.7B | 42 | Hold |
Peer medians: ROE -30.7% · P/E 26.9x · Gross margin 58.1%